Agile Therapeutics Inc expected to post a loss of $4.80 a share - Earnings Preview

Agile Therapeutics

29/04/2022 12:59

* Agile Therapeutics Inc  AGRX.OQ   AGRX.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Princeton New Jersey-based  company is expected to
report  a
1,160.3% increase in revenue to $1.462 million from $116
thousand a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Agile Therapeutics
Inc is
for a loss of $4.80 per share. For the same quarter last year,
the company reported a loss of $8.00 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $80​, above​ its last closing price
of $2.62. ​​​

This summary was machine generated April 29 at 11:59 GMT.  All
figures in US dollars  unless otherwise stated